Abstract:It has been demonstrated that anti-PD-1 immunotherapy may have potentially life-threatening side effect (i.e., autoimmune myocarditis with consequent cardiac failure). The purpose of this work was to determine the incidence and severity of radiation-induced cardiac mortality and morbidity in a murine model when cardiac irradiation is delivered concurrently with an anti-PD-1 antibody. Single fraction (20 Gy) was delivered specifically to the heart of female C57bl/6 mice with an image-guided SARRP, which allows on-board micro-CT imaging and real-time treatment planning. Mice were stratified into 4 treatment groups: (1) control IgG (n = 10); (2) anti-PD1 antibody (n = 10); (3) RT+ control IgG (n = 20); and (4) RT + anti-PD1 antibody (n = 20). Anti-CD4 and anti-CD8 antibodies were combined with RT and anti-PD1 antibody treatment to deplete subsets of T cells. Antibodies were intraperitoneally administrated 24 hours before of RT, and then every other day. Overall survival was determined. Echocardiographic assessment on all mice was performed to measure the cardiac contraction and output when clinical morbidity was encountered. The sick mice were then sacrificed for tissue collections, which were characterization by immunofluorescence for immune cells infiltration. Decreased survival was observed when anti-PD-1 was combined with RT: 35% (7/20) mortality vs. 0% mortality in other three groups (P < 0.05). The median survival following RT in the RT + Anti-PD1 group was day 8 (day 5 to 19). Ejection fraction (EF) and fractional shortening (FS) were used to measure cardiac function. Combined therapy group exhibited significantly decline in both EF and FS, especially compared with mice treated with RT + IgG control: the EFs of group 1 to 4: 62.43% ± 7.54%, 60.19% ± 5.81%, 50.85% ± 5.06%, and 38.84% ± 6.06%, P < 0.01; the FSs: 33.48% ± 5.48%, 31.66% ± 4.09%, 25.50% ± 3.13%, and 18.58% ± 3.28%, P < 0.01. These data indicates that 20 Gy induced cardiac dysfunction, which was exacerbates by anti-PD1 treatment. Myocarditis was observed in the dying mice after RT. Further immunologic data on heart tissue changed showed increased tumor infiltration by CD45, CD3, CD4, and CD8. Consistent with worse cardiac dysfunction, considerably more immune cells were observed in heart tissues of the dying mice from RT+ anti-PD1 compared with those from RT plus control IgG. To test which subset of T cells contributes to the myocarditis, neutralizing antibodies against CD4 and CD8 were combined with RT and anti-PD1 treatment. Consistently, depletion of CD8 T cells prevented mortality from RT plus anti-PD1 whereas depletion of CD4 did not, indicating that CD8+ lymphocytes mediates cardiac injury from RT + anti-PD1. The combination of PD-1 blockade increases the cardiac toxicity from irradiation through cytotoxic T cell-mediated myocarditis. Our study provides strong preclinical evidence that immune-related adverse events should be considered when PD-1 inhibitor is combined with RT.

Impact of Radiotherapy Concurrent with Anti-PD-1 Therapy on the Lung Tissue of Tumor-Bearing Mice.

Effect of PD-1 Inhibitor Combined with X-Ray Irradiation on the Inflammatory Microenvironment and Lung Tissue Injury in Mice

Combined Radiotherapy and Anti–PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non–Small Cell Lung Cancer

Alleviating lung injury and pulmonary fibrosis in radiotherapy-immunotherapy combination: The role of low-dose radiation therapy.

αPD-1 immunotherapy promotes IL-17A production and promotes the formation of acute radiation-induced lung injury.

PD-1 restrains IL-17A production from γδ T cells to modulate acute radiation-induced lung injury

Impact of Pulmonary microbiota on lung cancer treatment-related pneumonia

PD-1 Modulates Radiation-Induced Cardiac Toxicity Through Cytotoxic T Lymphocytes.

Impact of Clinicopathological Features on the Efficacy of Immune Checkpoint Inhibitors Plus Conventional Treatment in Patients with Advanced Lung Cancer

Impact of EGFR-TKIs combined with PD-L1 antibody on the lung tissue of EGFR-driven tumor-bearing mice

Radiation Exposure–Induced Changes in the Immune Cells and Immune Factors of Mice with or Without Primary Lung Tumor

Pharmacological Inhibition of PD-1 Exacerbates Radiation-Induced Cardiac Toxicity Through Cytotoxic T Cell–Mediated Myocarditis

Irradiation and Anti-Pd-l1 Treatment Synergistically Promote Antitumor Immunity in Mice.

Research Progress on Radiotherapy Combined with Immunotherapy for Associated Pneumonitis During Treatment of Non-Small Cell Lung Cancer

Relationship Between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients with Advanced Non-Small-Cell Lung Cancer.

Anti-PD-L1 treatment to enhance the response of glioblastoma to radiation and produce long-term survival in mice.

Rethinking pulmonary toxicity in advanced non-small cell lung cancer in the era of combining anti-PD-1/PD-L1 therapy with thoracic radiotherapy

The Effect of Microwave Ablation Combined with Anti-PD-1 Monoclonal Antibody on T Cell Subsets and Long-Term Prognosis in Patients Suffering from Non-Small-Cell Lung Cancer

Efficacy and Safety of Immunoradiotherapy for Advanced Non-Small Cell Lung Cancer: a Retrospective Comparative Cohort Study

Safety and Efficacy of PD‐1/PD‐L1 inhibitors combined with radiotherapy in patients with non‐small‐cell lung cancer: a systematic review and meta‐analysis

Neutrophil‑to‑lymphocyte Ratio Reflects Lung Injury in Thoracic Radiotherapy and Immune Checkpoint Inhibitors Combination Therapy with Different Sequences.